MX2023006972A - Compuestos antagonistas de h4. - Google Patents
Compuestos antagonistas de h4.Info
- Publication number
- MX2023006972A MX2023006972A MX2023006972A MX2023006972A MX2023006972A MX 2023006972 A MX2023006972 A MX 2023006972A MX 2023006972 A MX2023006972 A MX 2023006972A MX 2023006972 A MX2023006972 A MX 2023006972A MX 2023006972 A MX2023006972 A MX 2023006972A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- antagonist compounds
- ameliorating
- disclosures
- receptors
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000003396 histamine H4 receptor antagonist Substances 0.000 title 1
- 102000004187 Histamine H4 receptors Human genes 0.000 abstract 1
- 108090000796 Histamine H4 receptors Proteins 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La descripción en la presente se relaciona a compuestos novedosos de la fórmula (1): y sales de los mismos, en donde Y, Z, R1 , R2 , R3 , R4 , R5 y n son definidos en la presente, y su uso en tratar, prevenir, mejorar, controlar o reducir el riesgo de trastornos asociados con los receptores de H4. (ver formula 1).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2019667.1A GB202019667D0 (en) | 2020-12-14 | 2020-12-14 | H4 antagonist comnpounds |
| PCT/GB2021/053286 WO2022129890A1 (en) | 2020-12-14 | 2021-12-14 | H4 antagonist compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023006972A true MX2023006972A (es) | 2023-07-31 |
Family
ID=74188996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023006972A MX2023006972A (es) | 2020-12-14 | 2021-12-14 | Compuestos antagonistas de h4. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240317775A1 (es) |
| EP (1) | EP4259637A1 (es) |
| JP (1) | JP2023552888A (es) |
| KR (1) | KR20230118921A (es) |
| CN (1) | CN116848125A (es) |
| AU (1) | AU2021404140A1 (es) |
| BR (1) | BR112023011749A2 (es) |
| CA (1) | CA3205015A1 (es) |
| GB (1) | GB202019667D0 (es) |
| IL (1) | IL303598A (es) |
| MX (1) | MX2023006972A (es) |
| WO (1) | WO2022129890A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102725291B (zh) * | 2009-10-29 | 2016-12-21 | 西特里斯药业公司 | 作为沉默调节蛋白调节剂的双环吡啶和相关的类似物 |
| AR093512A1 (es) * | 2012-11-16 | 2015-06-10 | Merck Patent Gmbh | Derivados heterociclicos como moduladores de la actividad de cinasas |
| JP2019525929A (ja) * | 2016-07-28 | 2019-09-12 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | Ｐａｒｋｉｎ酵素機能の小分子活性化因子 |
-
2020
- 2020-12-14 GB GBGB2019667.1A patent/GB202019667D0/en not_active Ceased
-
2021
- 2021-12-14 CA CA3205015A patent/CA3205015A1/en active Pending
- 2021-12-14 US US18/257,413 patent/US20240317775A1/en active Pending
- 2021-12-14 EP EP21834848.0A patent/EP4259637A1/en active Pending
- 2021-12-14 MX MX2023006972A patent/MX2023006972A/es unknown
- 2021-12-14 AU AU2021404140A patent/AU2021404140A1/en active Pending
- 2021-12-14 BR BR112023011749A patent/BR112023011749A2/pt unknown
- 2021-12-14 IL IL303598A patent/IL303598A/en unknown
- 2021-12-14 CN CN202180093613.2A patent/CN116848125A/zh active Pending
- 2021-12-14 WO PCT/GB2021/053286 patent/WO2022129890A1/en active Application Filing
- 2021-12-14 KR KR1020237023281A patent/KR20230118921A/ko unknown
- 2021-12-14 JP JP2023535993A patent/JP2023552888A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230118921A (ko) | 2023-08-14 |
| EP4259637A1 (en) | 2023-10-18 |
| CA3205015A1 (en) | 2022-06-23 |
| US20240317775A1 (en) | 2024-09-26 |
| GB202019667D0 (en) | 2021-01-27 |
| JP2023552888A (ja) | 2023-12-19 |
| BR112023011749A2 (pt) | 2023-10-31 |
| AU2021404140A1 (en) | 2023-07-27 |
| AU2021404140A9 (en) | 2024-07-11 |
| CN116848125A (zh) | 2023-10-03 |
| IL303598A (en) | 2023-08-01 |
| WO2022129890A1 (en) | 2022-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022011333A (es) | Compuestos moduladores de gpr52. | |
| MX2021004280A (es) | Derivados de pirazol como compuestos antagonistas de receptor de histamina h4. | |
| CR20230310A (es) | Inhibidores de prmt5 | |
| MX2022005111A (es) | Compuestos moduladores del receptor 52 acoplado a proteina g (gpr52). | |
| MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
| SE0202462D0 (sv) | Novel use | |
| CR20200553A (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos | |
| MX2022007130A (es) | Derivados de piperazina sustituidos utiles como activadores de celulas t. | |
| HK1138265A1 (en) | Materials and methods for treating coagulation disorders | |
| MX2023001298A (es) | Combinaciones para el tratamiento de cancer. | |
| MX2022000812A (es) | Metodos de tratamiento de hiperplasia suprarrenal congenita. | |
| NZ582284A (en) | Carbamoyl-cyclohexanes for treating acute mania | |
| PH12021551157A1 (en) | Ketamine pamoate and use thereof | |
| MX2022009243A (es) | Moduladores de la via de respuesta integrada al estres. | |
| MX2022000550A (es) | Imidazopirimidinas como inhibidores de eed y uso de estas. | |
| MX2019010898A (es) | Compuestos de tipo imidazo[4,5-c]quinolin-2-ona deuterados y su uso en el tratamiento del cancer. | |
| MX2023012555A (es) | Compuestos agonistas de gpr35. | |
| SE0302756D0 (sv) | Novel Compounds | |
| ZA202212095B (en) | Il4i1 inhibitors and methods of use | |
| MX2022001429A (es) | Formulaciones que incluyen dihidrohonokiol. | |
| MX2023006972A (es) | Compuestos antagonistas de h4. | |
| MX2022004155A (es) | Compuestos antagonistas del receptor 4 de prostaglandina e2 (ep4). | |
| MX2022013482A (es) | Compuestos utiles para inhibir la quinasa ret. | |
| MX2022011561A (es) | Agonistas del receptor de glp. | |
| MX2023003332A (es) | Inhibidores del elemento 1 interdispersado largo (line-1) para el tratamiento de enfermedades. |